Under‑Resourced and Over‑Accountable: The UAT Dilemma for Small and Mid‑Size Sponsors

User Acceptance Testing (UAT) is a key step in clinical trial execution and one of the most consistently misunderstood. For small and mid-size biotech sponsors, UAT lives in a difficult space. Teams are lean. Timelines are compressed. Vendors play a central role in delivery. Yet accountability never shifts. Regulators still expect sponsors to demonstrate clear ownership, a risk-based approach, and inspection-ready documentation across every system, including IRT, eCOA, and eConsent.

That tension is where many studies start to break down, not during testing itself, but when sponsors are asked to explain how and why testing was done.

The Reality of UAT in Clinical Trials Today

Across clinical operations teams, the pattern is consistent. A single clinical lead is often managing multiple responsibilities across study startup, vendor coordination, and execution. Dedicated UAT expertise is rare. Testing is frequently supported by vendors or CROs, and timelines leave little room to challenge assumptions or iterate.

At the same time, expectations around UAT for clinical trial systems have become more stringent. Regulators expect sponsors to clearly articulate:

• How UAT scope aligns to protocol risk
• Why specific scenarios were included or excluded
• How testing reflects real-world study execution
• Who owned the process and approved outcomes
When those answers are unclear, even a completed UAT effort can introduce inspection risk.

Where UAT Starts to Break Down

Most emerging sponsors are not lacking commitment to quality. They are lacking a repeatable, defensible framework for clinical trial UAT. Without a formalized internal process, UAT becomes reactive. It follows vendor templates rather than sponsor-defined priorities. Testing confirms that systems function but not necessarily that they will perform under real study conditions.

Time constraints make this worse. Review cycles are compressed. Edge cases go untested. Scenarios tied to supply logistics, patient behavior, or protocol complexity are often overlooked. This is especially true in IRT UAT, where the difference between “system works” and “study works” can have direct implications for blinding, dosing, and patient safety.

Why Sponsors Are Rethinking the UAT Model

Building a fully internal UAT capability sounds ideal, but in practice, it is rarely realistic for small or mid-size organizations. As a result, more sponsors are adopting a different model by bringing in independent, third-party expertise to support risk-based UAT for clinical trials while retaining ownership.

When done correctly, this approach creates a much stronger position operationally and during inspection. It introduces structure without adding long-term overhead. It also creates separation between system validation and sponsor accountability, something regulators increasingly expect.

A More Practical Approach to UAT for Clinical Trial Systems

A well-structured UAT model should do three things. First, it should align testing directly to protocol risk, not generic system functionality. Second, it should produce clear, traceable documentation that stands up to inspection. Third, it should reflect how the study will actually operate, not just how the system was built.

This is where independent UAT support becomes valuable. It allows sponsors to move faster while increasing confidence in outcomes.

More importantly, it changes the narrative from relying on the vendor to applying a defined, risk-based UAT strategy with clear sponsor oversight. That distinction matters.

UAT is a Regulatory Control Point.

UAT in clinical trials is no longer a procedural step. It is a regulatory and operational control point. For small and mid-size sponsors, the challenge is not understanding its importance. It is having the structure, time, and expertise to execute it in a way that is both efficient and defensible.

The organizations that get this right are not necessarily the ones with the largest teams. They are the ones that approach UAT for clinical trial systems as a strategic function, one that directly impacts study quality, timelines, and inspection readiness. Because when questions come during an audit, completion is not enough. Clarity is.

Want to pressure-test your UAT approach?

Let’s chat to assess your readiness and identify potential gaps before they impact your study. With CSC’s expert-led approach, every test is an opportunity to protect your trial’s supply chain and your reputation. Learn more about CSC’s UAT Services.